You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
NameDesoxycorticosterone Pivalate
Accession NumberDB01134  (APRD00709)
TypeSmall Molecule

Desoxycorticosterone Pivalate is a mineralocorticoid hormone and an analog of desoxycorticosterone. It is white, odorless, and stable in air. It is practically insoluble in water, sparingly soluble in acetone, slightly soluble in methanol, ether and vegetable oils. Federal (U.S.A.) law restricts this drug to use by or on the order of a licensed veterinarian.

Deoxycorticosterone PivalateNot AvailableNot Available
Deoxycorticosterone TrimethylacetateNot AvailableNot Available
Deoxycortolone PivalateNot AvailableNot Available
Deoxycortone PivalateNot AvailableNot Available
Deoxycortone TrimethylacetateNot AvailableNot Available
Desoxycorticosterone TrimethylacetateNot AvailableNot Available
Desoxycortone PivalateNot AvailableNot Available
DOCPNot AvailableNot Available
DTMANot AvailableNot Available
External Identifiers Not Available
Prescription ProductsNot Available
Generic Prescription ProductsNot Available
Over the Counter ProductsNot Available
International Brands
Cortexone MNot Available
Neodin-DepositumNot Available
PercortenNot Available
Percorten MNot Available
Percorten PivalateNot Available
Brand mixturesNot Available
SaltsNot Available
CategoriesNot Available
CAS number808-48-0
WeightAverage: 414.5775
Monoisotopic: 414.277009704
Chemical FormulaC26H38O4
2-{2,15-dimethyl-5-oxotetracyclo[²,⁷.0¹¹,¹⁵]heptadec-6-en-14-yl}-2-oxoethyl 2,2-dimethylpropanoate
DescriptionThis compound belongs to the class of organic compounds known as gluco/mineralocorticoids, progestogins and derivatives. These are steroids with a structure based on a hydroxylated prostane moiety.
KingdomOrganic compounds
Super ClassLipids and lipid-like molecules
ClassSteroids and steroid derivatives
Sub ClassPregnane steroids
Direct ParentGluco/mineralocorticoids, progestogins and derivatives
Alternative Parents
  • Progestogin-skeleton
  • 20-oxosteroid
  • Oxosteroid
  • 3-oxosteroid
  • 3-oxo-delta-4-steroid
  • Delta-4-steroid
  • Alpha-acyloxy ketone
  • Cyclic ketone
  • Ketone
  • Carboxylic acid ester
  • Monocarboxylic acid or derivatives
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Carbonyl group
  • Aliphatic homopolycyclic compound
Molecular FrameworkAliphatic homopolycyclic compounds
External DescriptorsNot Available
IndicationExamined for treatment of adrenocortical insufficiency especially in multiple sclerosis, congenital cerebral palsy, polyarteritis nodosa, and rheumatoid arthritis. Currently only approved in treating cats and dogs for the treatment of Addison's disease.
PharmacodynamicsUsed to treat adrenocortical insufficiency, desoxycorticosterone pivalate is a mineralocorticoid hormone and an analogue of desoxycorticosterone. It primarily acts on the metabolism of sodium, potassium and water. When the drug is given, there is decreased excretion of sodium accompanied by increased excretion of potassium; the concentration of sodium in the blood is thereby increased whereas that of potassium is decreased. There is a concomitant increase in the volume of blood and extracellular fluids, with a fall in hematocrit. It increases the rate of renal tubular absorption of sodium.
Mechanism of actionDesoxycorticosterone Pivalate binds to the mineralocorticoid receptor. Mineralocorticoids are a family of steroids, secreted by the adrenal cortex, necessary for the regulation of a number of metabolic processes including electrolyte regulation. Desoxycorticosterone pivalate exerts its effect through its interaction with the mineralocorticoid receptor (MR), whereby it reacts with the receptor proteins to form a steroid-receptor complex. This complex moves into the nucleus, where it binds to chromatin which results in genetic transcription of cellular DNA to messenger RNA. The steroid hormones appear to induce transcription and synthesis of specific proteins, which produce the physiological effects seen after administration.
AbsorptionNot Available
Volume of distributionNot Available
Protein binding90%
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicitySymptoms of overdose include polyuria, polydipsia, increased blood volume, edema, and cardiac enlargement.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Predicted ADMET features
Human Intestinal Absorption+0.9954
Blood Brain Barrier+0.9553
Caco-2 permeable+0.6211
P-glycoprotein substrateSubstrate0.6541
P-glycoprotein inhibitor IInhibitor0.9048
P-glycoprotein inhibitor IIInhibitor0.8603
Renal organic cation transporterNon-inhibitor0.6993
CYP450 2C9 substrateNon-substrate0.8702
CYP450 2D6 substrateNon-substrate0.9101
CYP450 3A4 substrateSubstrate0.8098
CYP450 1A2 substrateNon-inhibitor0.9498
CYP450 2C9 inhibitorNon-inhibitor0.8229
CYP450 2D6 inhibitorNon-inhibitor0.9356
CYP450 2C19 inhibitorNon-inhibitor0.8875
CYP450 3A4 inhibitorNon-inhibitor0.8554
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7501
Ames testNon AMES toxic0.9473
BiodegradationNot ready biodegradable0.9231
Rat acute toxicity1.7883 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9494
hERG inhibition (predictor II)Non-inhibitor0.7297
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
ManufacturersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Experimental Properties
water solubilityInsolubleNot Available
logP4Not Available
Predicted Properties
Water Solubility0.00141 mg/mLALOGPS
pKa (Strongest Acidic)17.19ChemAxon
pKa (Strongest Basic)-4.8ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area60.44 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity117.26 m3·mol-1ChemAxon
Polarizability48.32 Å3ChemAxon
Number of Rings4ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Mass Spec (NIST)Not Available
SpectraNot Available
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesNot Available
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (65.5 KB)
Drug InteractionsNot Available
Food InteractionsNot Available


1. Mineralocorticoid receptor

Kind: protein

Organism: Human

Pharmacological action: yes

Actions: agonist


Name UniProt ID Details
Mineralocorticoid receptor P08235 Details


  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. Pubmed
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. Pubmed
  3. Beaumont K, Fanestil DD: Characterization of rat brain aldosterone receptors reveals high affinity for corticosterone. Endocrinology. 1983 Dec;113(6):2043-51. Pubmed
  4. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. Pubmed
  5. Sekihara H, Island DP, Liddle GW: New mineralocorticoids: 5alpha-dihydroaldosterone and 5alpha-dihydro-11-deoxycorticosterone. Endocrinology. 1978 Oct;103(4):1450-2. Pubmed

comments powered by Disqus
Drug created on June 13, 2005 07:24 /Updated on September 16, 2013 17:13